STOCK TITAN

MDxHealth SA (MDXH) Financials

MDXH
FY2025 annual
Revenue $107.9M +19.8% YoY
Net Income -$33.5M +12.0% YoY
Free Cash Flow -$3.3M +83.0% YoY
Operating Cash Flow -$2.2M +88.2% YoY
Market Cap $20.5M as of Oct 21, 2026
Price / Sales 0.2x on $107.9M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book n/m negative shareholder equity, so no book multiple, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Apr 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDXH SEC filings page.

MDxHealth SA (MDXH) reported $107.9M in revenue for fiscal year 2025, up 19.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MDXH FY2025

Revenue has scaled to $108M, while losses persist and liabilities now exceed assets, leaving growth dependent on financing.

Between FY2023 and FY2025, revenue rose from $70.2M to $107.9M while the net loss narrowed from $43.1M to $33.5M, showing improvement without reaching profitability. Operating cash flow improved from an outflow of $21.5M to $2.2M, and free cash flow moved from -$24.2M to -$3.3M; cash conversion is approaching balance faster than accounting earnings.

The balance sheet shifted from positive equity of $14.8M in FY2024 to negative -$12.1M in FY2025 as liabilities moved above assets, a structural solvency change rather than merely a short-term liquidity squeeze. The current ratio fell from 1.6x to 1.1x, leaving only modest coverage of near-term obligations.

FY2025 investing cash flow was an outflow of $18.6M against only $1.2M of capital expenditures, indicating that cash use was driven largely by non-routine investing rather than ordinary asset upkeep. With operating cash flow still an outflow of $2.2M and financing cash flow of $3.0M, operations had not yet funded all cash needs.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

MDxHealth SA does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial
3/8

MDxHealth SA passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

MDxHealth SA reported a net loss of $33.5M while operations used $2.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt
$29.0M
YoY-38.0%
QoQ-38.0%

MDxHealth SA held $29.0M in cash against $8.5M in long-term debt as of Q4 2025.

Shares Outstanding
51M
YoY+3.8%
QoQ+3.8%

MDxHealth SA had 51M shares outstanding in Q4 2025. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 3.8%.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

MDXH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXH quarterly income statement
MetricQ4'2520-FQ4'2420-FQ4'2310-KQ4'2210-KQ4'2110-KQ4'2010-K

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

MDXH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXH quarterly balance sheet
MetricQ4'2520-FQ4'2420-FQ4'2310-KQ4'2210-KQ4'2110-KQ4'2010-K
Total Assets$148.0M-6.0%$157.3M+21.8%$129.1M+8.4%$119.1M+58.7%$75.1M+135.7%$31.9M
Current Assets$53.4M-20.2%$66.9M+75.3%$38.2M+30.9%$29.1M-56.2%$66.6M+188.5%$23.1M
Cash & Equivalents$29.0M-38.0%$46.8M+109.1%$22.4M+44.4%$15.5M-73.5%$58.5M+266.7%$16.0M
Inventory$6.7M+74.2%$3.9M+39.2%$2.8M+19.4%$2.3M+21.8%$1.9M-17.8%$2.3M
Accounts Receivable$14.7M+1.6%$14.4M+30.2%$11.1M+18.5%$9.4M+104.2%$4.6M+21.5%$3.8M
Goodwill$38.9M+8.4%$35.9M0.0%$35.9M0.0%$35.9M$0N/A
Total Liabilities$160.0M+12.3%$142.5M+16.9%$121.9M+11.0%$109.8M+289.8%$28.2M+8.3%$26.0M
Current Liabilities$49.5M+16.1%$42.7M+118.5%$19.5M+6.8%$18.3M+11.2%$16.4M+26.2%$13.0M
Non-Current Liabilities$110.5M+10.7%$99.8M-2.5%$102.4M+11.9%$91.5M+679.7%$11.7M-9.6%$13.0M
Long-Term Debt$8.5M+14.8%$7.4M+107.2%$3.6M+15.8%$3.1M+17.8%$2.6M+30.1%$2.0M
Total Equity-$12.1M-181.5%$14.8M+105.9%$7.2M-22.6%$9.3M-80.1%$46.9M+701.8%$5.8M
Retained Earnings-$403.0M-9.1%-$369.5M-11.5%-$331.4M-14.9%-$288.3M-18.0%-$244.3M-13.5%-$215.3M

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

MDXH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXH quarterly cash flow statement
MetricQ4'2520-FQ4'2420-FQ4'2310-KQ4'2210-KQ4'2110-KQ4'2010-K

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

MDXH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXH quarterly financial ratios
MetricQ4'2520-FQ4'2420-FQ4'2310-KQ4'2210-KQ4'2110-KQ4'2010-K
Current Ratio1.08-0.5x1.57-0.4x1.95+0.4x1.59-2.5x4.05+2.3x1.77
Debt-to-EquityN/A0.500.0x0.50+0.2x0.33+0.3x0.06-0.3x0.34

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$12.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
MDxHealth SA MDXH FY2025 $107.9M -$33.5M -31.1% $20.5M —
Exagen Inc. XGN FY2025 $66.6M -$20.0M -30.0% $190.9M 47/100
Prenetics Global Limited PRE FY2025 $92.4M -$40.0M -43.3% $326.5M 40/100
Burning Rock Biotech Limited BNR FY2025 $77.2M -$7.9M -10.3% $142.5M 60/100
Fonar Corporation FONR FY2025 $104.4M $8.3M 8.0% $120.2M 63/100
Biodesix, Inc. BDSX FY2025 $88.5M -$35.3M -39.9% $252.5M 51/100

Frequently Asked Questions

What is MDxHealth SA's annual revenue?

MDxHealth SA (MDXH) reported $107.9M in total revenue for fiscal year 2025. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MDxHealth SA's revenue growing?

MDxHealth SA (MDXH) revenue grew by 19.8% year-over-year, from $90.0M to $107.9M in fiscal year 2025.

Is MDxHealth SA profitable?

No, MDxHealth SA (MDXH) reported a net income of -$33.5M in fiscal year 2025, with a net profit margin of -31.1%.

As of fiscal year 2025, MDxHealth SA (MDXH) had $29.0M in cash and equivalents against $8.5M in long-term debt.

MDxHealth SA (MDXH) had a net profit margin of -31.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

MDxHealth SA (MDXH) recorded an outflow of $3.3M in free cash flow during fiscal year 2025. This represents a 83.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

MDxHealth SA (MDXH) recorded an outflow of $2.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

MDxHealth SA (MDXH) had $148.0M in total assets as of fiscal year 2025, including both current and long-term assets.

MDxHealth SA (MDXH) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

MDxHealth SA (MDXH) had 51M shares outstanding as of fiscal year 2025.

MDxHealth SA (MDXH) had a current ratio of 1.08 as of fiscal year 2025, which is considered adequate.

MDxHealth SA (MDXH) had a return on assets of -22.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

MDxHealth SA (MDXH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $20.5M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

MDxHealth SA (MDXH) trades at 0.2x sales, its market capitalization divided by revenue of $107.9M revenue, FY2025. The market capitalization is $20.5M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

MDxHealth SA (MDXH) has negative shareholder equity of -$12.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

MDxHealth SA (MDXH) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

MDxHealth SA (MDXH) reported a net loss of $33.5M while operations used $2.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top